Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1983 1
1990 4
1991 2
1992 1
1993 1
1994 2
1996 1
1998 4
1999 4
2001 1
2002 1
2003 2
2004 2
2005 1
2006 2
2008 2
2010 1
2011 1
2012 3
2013 2
2015 4
2016 2
2017 2
2018 1
2019 2
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group. Jayne DRW, et al. Among authors: bekker p. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11. J Am Soc Nephrol. 2017. PMID: 28400446 Free PMC article. Clinical Trial.
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P. Merkel PA, et al. Among authors: bekker p. JMIR Res Protoc. 2020 Apr 7;9(4):e16664. doi: 10.2196/16664. JMIR Res Protoc. 2020. PMID: 32088663 Free PMC article.
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A, Pagnoux C, Potarca A, Schall TJ, Bekker P; CLASSIC Investigators. Merkel PA, et al. Among authors: bekker p. ACR Open Rheumatol. 2020 Nov;2(11):662-671. doi: 10.1002/acr2.11185. Epub 2020 Oct 31. ACR Open Rheumatol. 2020. PMID: 33128347 Free PMC article.
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ. Bekker P, et al. PLoS One. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646. eCollection 2016. PLoS One. 2016. PMID: 27768695 Free PMC article. Clinical Trial.
Denosumab in postmenopausal women with low bone mineral density.
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. McClung MR, et al. Among authors: bekker pj. N Engl J Med. 2006 Feb 23;354(8):821-31. doi: 10.1056/NEJMoa044459. N Engl J Med. 2006. PMID: 16495394 Free article. Clinical Trial.
Enhanced Recovery After Surgery in Laparoscopic Surgery.
Leissner KB, Shanahan JL, Bekker PL, Amirfarzan H. Leissner KB, et al. Among authors: bekker pl. J Laparoendosc Adv Surg Tech A. 2017 Sep;27(9):883-891. doi: 10.1089/lap.2017.0239. Epub 2017 Aug 22. J Laparoendosc Adv Surg Tech A. 2017. PMID: 28829221 Review.
53 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page